Reuters logo
BRIEF-Endocyte says ABX GmbH eligible for milestones of up to $160 mln under license agreement
October 2, 2017 / 3:26 PM / 15 days ago

BRIEF-Endocyte says ABX GmbH eligible for milestones of up to $160 mln under license agreement

Oct 2 (Reuters) - Endocyte Inc :

* Endocyte Inc - ‍ABX is eligible for regulatory and commercial milestones of up to $160 million, and tiered royalties beginning in mid-teens​

* Endocyte Inc - Intends to move quickly into phase 3 development of( 177)LU-PSMA-617, a radioligand therapeutic​

* Endocyte Inc - Phase 3 registration trial of( 177)LU-PSMA-617 planned to initiate in first half 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below